Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Arrayit Corporation (ARYC)
Sunnyvale, CA, US
Arrayit Corporation, headquartered in Sunnyvale, California, operates as a global life sciences technology firm. The company is dedicated to developing, manufacturing, and commercializing advanced tools and integrated systems for comprehensive analysis of genetic variations, biological functions, and diagnostic applications worldwide. Its core activities encompass the creation and maintenance of microarray instruments and components, providing bespoke microarray printing and analysis services for research, and pioneering diagnostic microarrays designed for the early identification of treatable health conditions. Arrayit's innovative microarray printing technology facilitates the production of diverse microarray types—including DNA, protein, antibody, lipid, and carbohydrate—suitable for a wide array of research and diagnostic uses such as gene expression studies, genotyping, and protein profiling. The company's product portfolio extends to automated microarray manufacturing instruments like the NanoPrint, various SpotBot models (Titan, Extreme, Protein), and Personal microarrayers. It also supplies a range of scanning devices, including SpotLight CCD and SpotWare colorimetric scanners, InnoScan laser scanners, alongside hybridization stations (TrayMix, ArrayMix), centrifuges, air jets, vacuum equipment, general laboratory tools, and bioinformatics computing solutions. Additionally, Arrayit manufactures essential consumables such as glass substrates and slides, reagents, solutions, kits, and clean room provisions. A notable offering is its variation identification platform technology, which enables diagnostic tests by accommodating approximately 100,000 patient samples on a single microarray. The company further diversifies its operations through the import, export, manufacture, and distribution of wholesale industrial chemicals. Arrayit Corporation serves a broad spectrum of clients, including genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, government agencies, and biotechnology firms.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -90.00% | -90.00% | -90.00% | -90.00% | -90.00% | +0.00% | -98.00% | -98.33% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Diagnostics & Research: +7.9%+50.8% ★ Q3'15: +24.9% (vs Q3'14)
-
EPS growth Medical - Diagnostics & Research: +30.8%-500.8% Q3'15: +25.2% (vs Q3'14)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%-99.6% Q3'15: +1.0% (vs Q3'14)
-
EBIT margin Medical - Diagnostics & Research: +9.6%-71.2% Q3'15: -519.8% (vs Q3'14)
-
ROIC Medical - Diagnostics & Research: +5.2%— Q3'15: +216.0% (vs Q3'14)
-
Share dilution Medical - Diagnostics & Research: 0.0%+45.0% Q3'15: +942.7% (vs Q3'14)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×-0.35× Q3'15: -0.07× (vs Q3'14)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Todd J. Martinsky | Founder, Executive Vice President, Scientific Advisor & Director | 84.4K | male |
| Rene A. Schena | Chairman, Chief Executive Officer & Chief Financial Officer | 78.8K | female |
| Mark Schena | President, Chief Science Officer, Treasurer, Secretary, Scientific Advisor & Director | 5.6K | — |
| Paul K. Haje | Vice President of Sales & Marketing | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ARYC
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
